Full Press Release Details
dupixent dupilumab sbla accepted for fda priority review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis crswnp.
REGN
dupixent dupilumab sbla accepted for fda priority review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis crswnp
Key Takeaway: dupixent dupilumab sbla accepted for fda priority review for treatment of adolescents with chronic rhinosinusitis with nasal polyposis crswnp